Pilot Study for validation of the MDS-NMS Rater-Administered Scale
Research type
Research Study
Full title
The International Parkinson and Movement Disorder Society (MDS) Non-Motor Symptom (NMS) Scale: A pilot study for the validation of a rater-administrated scale.
IRAS ID
161295
Contact name
K Ray Chaudhuri
Contact email
Sponsor organisation
Kings College London
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Non-motor symptoms (NMS) range from depression/dementia, to sleep dysfunction and pain and are a key part of the symptoms of Parkinson's Disease (PD), and can be present from before a diagnosis of PD right up until the most advanced stages. Parkinson’s is now known to be as much a non-motor disorder as a motor disorder. NMS present the single biggest challenge to clinicians dealing with Parkinson’s. PD patients typically exhibit 6-10 non-motor symptoms and NMS are recognized as an important unmet need in PD in the UK by NICE and are a frequent cause of hospitalisation and institutionalization with serious social/economic consequences.
Management of NMS of PD depends on bedside measurement and for this purpose the NMS Questionnaire (allowing patients to declare NMS in the clinic) and the NMS scale (NMSS)(used by health care professionals) were developed and are used worldwide being recommended by NHS England and patient societies. However, since the development of NMSS, several new developments have occurred which are not captured in the 2007 version of the NMSS. These include structure of the NMSS, missing items such as drug induced NMS (impulse control disorders) as well as the way some symptoms are grouped in the scale. The new scale will acknowledge these and also include fluctuating symptoms of NMS according to the state of the patient.
With support of the International Parkinson’s and Movement Disorders Society, we have now developed a new and advanced version of the NMSS, called the MDS-NMS which incorporates the missing items and uses a new refined structure. The current proposal is part of a 4 phase study which will aim to validate (using accepted methods) the use of the “new” MDS-NMS in people with Parkinson’s and normal healthy controls (required for any scale validation) to international and subsequent worldwide use.REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
14/EM/1211
Date of REC Opinion
31 Oct 2014
REC opinion
Further Information Favourable Opinion